A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
ApexOnco Front Page
Recent articles
With a slashed valuation the newly listed biotech heads for phase 3.
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
But more detail is awaited, especially on toxicity.
